About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in New York | 215 Studies

Clinical Trials LymphomaNew York

Lymphoma Clinical Trials in New York

Find 215 clinical trials for lymphoma near New York, New York. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in New York

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 61-80 of 215 trials

CompletedRituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)This study is designed as a Phase III, multicenter trial, comparing progression-free survival (PFS) after autologous hematopoietic stem cell transplantation using a standard…NCT00329030·New Haven, Connecticut and 35 others

Lymphoma Trials in Other Cities

Los Angeles Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

CompletedLiposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell LymphomaRATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin and bexarotene, work in different ways to stop the growth of cancer cells, either by killing the cells or by…NCT00255801·Hackensack, New Jersey and 4 others

CompletedCombination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy, such as doxorubicin, vinblastine, and gemcitabine, work in different ways to stop cancer cells from dividing so they stop growing or die.NCT00086801·San Francisco, California and 46 others

RecruitingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLThis is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or…NCT06500273·Gilbert, Arizona and 82 others

CompletedPentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00026351·Rancho Mirage, California and 4 others

Active not recruitingA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell MalignanciesThis study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of…NCT05207670·Mobile, Alabama and 38 others

UnknownMogamulizumab Q4week Dosing in Participants With R/R CTCLThis is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with…NCT04745234·Duarte, California and 15 others

CompletedA Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or…NCT02500407·La Jolla, California and 34 others

CompletedPh I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLThe purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of…NCT00546793·Savannah, Georgia and 4 others

CompletedEfficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin LymphomasThe primary objective will be to assess the overall response rate and to evaluate the efficacy and safety of idelalisib (IDELA; GS-1101) in participants with previously treated…NCT01282424·Fullerton, California and 40 others

CompletedStudy of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell LymphomaThe purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.NCT00849654·Palo Alto, California and 8 others

UnknownRituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's LymphomaThe purpose of this study is to evaluate the ability of patients treated with Rituxan® plus FavId™ and GM-CSF to mount an immune response (humoral and/or cellular) to KLH and…NCT00041730·La Jolla, California and 14 others

UnknownBAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00039156·Miami Beach, Florida and 14 others

UnknownCombination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00017290·Dublin, California and 23 others

TerminatedDonor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantRATIONALE: Giving chemotherapy, such as busulfan and fludarabine phosphate, before a peripheral blood stem cell transplant helps stop the growth of cancer cells.NCT01118013·Lewes, Delaware and 9 others

UnknownCombination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00006250·Aylesbury-Buckinghamshire, England and 58 others

CompletedCLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell MalignanciesCLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or…NCT04450069·Duarte, California and 7 others

CompletedCombination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.NCT00006747·Birmingham, Alabama and 47 others

UnknownR-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell LymphomaThis phase I/II trial studies the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and to see how well they…NCT02628405·Jacksonville, Florida and 11 others

CompletedS0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.NCT00006721·Anchorage, Alaska and 258 others

PreviousPage 4 of 11Next

Other Conditions in New York

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia